ASR Vermogensbeheer N.V. Invests $12.12 Million in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Key Points

• ASR Vermogensbeheer N.V. has made a new investment of $12.12 million in shares of Intuitive Surgical, purchasing 24,470 shares valued at approximately this amount.
• Numerous hedge funds have updated their positions in Intuitive Surgical, with institutional investors collectively owning 83.64% of the company's stock.
• A variety of analysts have revised their price targets for Intuitive Surgical, resulting in an average target of $595.95, while the company's stock is currently trading around $474.06.

ASR Vermogensbeheer N.V. purchased a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 24,470 shares of the medical equipment provider's stock, valued at approximately $12,119,000.

A number of other hedge funds have also recently modified their holdings of ISRG. Brighton Jones LLC grew its position in Intuitive Surgical by 24.9% in the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock worth $1,916,000 after acquiring an additional 731 shares during the period. Bank Pictet & Cie Europe AG lifted its stake in shares of Intuitive Surgical by 0.5% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 190,969 shares of the medical equipment provider's stock valued at $99,678,000 after purchasing an additional 883 shares during the last quarter. Bernard Wealth Management Corp. purchased a new position in shares of Intuitive Surgical during the 4th quarter worth $56,000. Azimuth Capital Investment Management LLC increased its position in shares of Intuitive Surgical by 6.9% during the 4th quarter. Azimuth Capital Investment Management LLC now owns 42,232 shares of the medical equipment provider's stock worth $22,043,000 after purchasing an additional 2,713 shares during the last quarter. Finally, APG Asset Management US Inc. purchased a new stake in Intuitive Surgical in the 4th quarter valued at about $3,833,000. Hedge funds and other institutional investors own 83.64% of the company's stock.

Insiders Place Their Bets

In other Intuitive Surgical news, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $563.11, for a total transaction of $121,631.76. Following the sale, the senior vice president owned 907 shares of the company's stock, valued at approximately $510,740.77. This trade represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Myriam Curet sold 4,500 shares of the business's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the sale, the executive vice president owned 353 shares of the company's stock, valued at $173,845.44. This represents a 92.73% decrease in their position. The disclosure for this sale can be found here. Insiders sold 15,903 shares of company stock valued at $7,932,778 in the last ninety days. Insiders own 0.70% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have commented on ISRG shares. Barclays decreased their target price on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. Royal Bank Of Canada increased their price objective on shares of Intuitive Surgical from $605.00 to $615.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft downgraded shares of Intuitive Surgical from a "hold" rating to a "sell" rating and dropped their target price for the company from $515.00 to $440.00 in a report on Monday, June 9th. Truist Financial upped their price target on Intuitive Surgical from $590.00 to $600.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Finally, Piper Sandler restated an "overweight" rating and set a $595.00 price target (up from $575.00) on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the company's stock. According to MarketBeat.com, Intuitive Surgical currently has an average rating of "Moderate Buy" and a consensus price target of $595.95.

Intuitive Surgical Stock Down 0.6%

Shares of Intuitive Surgical stock opened at $474.06 on Thursday. Intuitive Surgical, Inc. has a 52-week low of $425.00 and a 52-week high of $616.00. The company has a market capitalization of $169.94 billion, a P/E ratio of 66.12, a P/E/G ratio of 5.00 and a beta of 1.59. The company has a 50 day moving average of $519.86 and a 200 day moving average of $531.12.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.93 by $0.26. The business had revenue of $2.44 billion during the quarter, compared to analysts' expectations of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The company's revenue for the quarter was up 21.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.78 EPS. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.